Jason Haas
Chief Financial Officer; Director · 4 filings · Latest: Aug 12, 2026
LIGAND PHARMACEUTICALS INC
Odyssey Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
LGND | Jason Haas | Director | Aug 12, 2026 | Sale | $292.81 | 7,138 | $2.1M | 3,981 | |
LGND | Jason Haas | Director | Aug 12, 2026 | Option Exercise | $51.56 | 6,138 | $316.5K | 11,119 | |
LGND | Jason Haas | — | Aug 12, 2026 | Proposed Sale | $292.81 | 7,138 | $2.1M | — | |
LGND | Jason Haas | Director | Jun 12, 2026 | Sale | $255.58 | 6,461 | $1.7M | 4,981 | |
LGND | Jason Haas | Director | Jun 12, 2026 | Option Exercise | $51.56 | 4,000 | $206.2K | 11,442 | |
LGND | JASON HAAS | — | Jun 12, 2026 | Proposed Sale | $256.00 | 6,461 | $1.7M | — | |
ODTX | Jason Haas | Chief Financial Officer | May 8, 2026 | Purchase | $20.00 | 1,000 | $20.0K | 62,908 | |
— | Haas Jason | — | Nov 18, 2024 | Proposed Sale | $0.2293 | 37,803 | $8.7K | — | |
— | JASON HAAS | — | Nov 18, 2024 | Proposed Sale | $0.2031 | 100,000 | $20.3K | — |